SecuritySYBX / Synlogic, Inc. (60470J103)
IndustryPharmaceutical Preparations
Common Shares Outstanding25,450,808 shares (as of 2018-03-31)
Total Insiders48
Total Directors15
Total Officers12

Stock Insider Trading (from SEC Form 4)

Synlogic, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

SYBX / Synlogic, Inc. insiders include Irvin Jon, Sofinnova Management VIII, L.L.C., SIEGALL CLAY B, Khuong Chau Quang, Alleva Lawrence M, O'Neill Vincent, ORBIMED ADVISORS LLC, Brennan Aoife, Shegog Todd, SANDELL SCOTT D, POWELL MICHAEL, Fuhrman Alan, Lammers Paul, Winkler Matthew, KERINS PATRICK J, DeYoung Casi, HEALY JAMES, Gengos Andrew, Miller Paul Francis, and BARRETT M JAMES, KOLLURI KRISHNA KITTU, Leschly Nick, Shea Richard P, ISALY SAMUEL D, PFIZER INC, Atlas Venture Fund IX, L.P., NEA Partners 14, L.P., Mathers Edward T, Weller Harry R, Gutierrez-Ramos Jose-Carlos Sofinnova Venture Partners VIII, L.P., MOTT DAVID M, Viswanathan Ravi, Kim Sinil, Florence Anthony A. Jr., Barrett Peter, NEA 14 GP, LTD, Sonsini Peter W., OrbiMed Capital GP VI LLC, Greenleaf Peter, BARRIS PETER J, AKKARAJU SRINIVAS, Barbosa Miguel, Nisen Perry, Jones Elaine V, BASKETT FOREST, Mehra Anand, New Enterprise Associates 14, L.P., .

Insider Roster

Insider Dir Off 10% Shares Owned
Miller Paul Francis Chief Scientific Officer
X 72,135
Leschly Nick Director
X
Barrett Peter Director
X
POWELL MICHAEL Director
X
Khuong Chau Quang Director
X
Shea Richard P Director
X
Mathers Edward T Director
X
Brennan Aoife Interim President and CEO
X
Gutierrez-Ramos Jose-Carlos See Remarks, Director
X X
Shegog Todd See Remarks
X
Gengos Andrew Chief Operating Officer
X
ORBIMED ADVISORS LLC Director
OrbiMed Capital GP VI LLC Director
X 2,029,996
Viswanathan Ravi 10% Owner
X 4,228,940
Sonsini Peter W. 10% Owner
X 4,228,940
SANDELL SCOTT D 10% Owner
X 4,228,940
MOTT DAVID M 10% Owner
X 4,228,940
KERINS PATRICK J 10% Owner
X 4,228,940
Florence Anthony A. Jr. 10% Owner
X 4,228,940
BASKETT FOREST 10% Owner
X 4,228,940
BARRIS PETER J 10% Owner
X 4,228,940
BARRETT M JAMES 10% Owner
X 4,228,940
New Enterprise Associates 14, L.P. 10% Owner
NEA Partners 14, L.P. 10% Owner
NEA 14 GP, LTD 10% Owner
X 4,228,940
NEA 14 GP, LTD 10% Owner
New Enterprise Associates 14, L.P. 10% Owner
NEA Partners 14, L.P. 10% Owner
X 3,818,940
Atlas Venture Fund IX, L.P. 10% Owner
X 5,303,926
Irvin Jon Vice President, Finance
X
Nisen Perry Director
X
Winkler Matthew Director
X
Alleva Lawrence M Director
X
SIEGALL CLAY B Director
X
Greenleaf Peter Director
X
O'Neill Vincent Chief Medical Officer
X
DeYoung Casi Chief Business Officer
X
Fuhrman Alan Chief Financial Officer
X
Lammers Paul President & CEO, Director
X X
PFIZER INC 10% Owner
X
AKKARAJU SRINIVAS 10% Owner
Sofinnova Venture Partners VIII, L.P. 10% Owner
Sofinnova Management VIII, L.L.C. 10% Owner
HEALY JAMES 10% Owner
Mehra Anand 10% Owner
X
KOLLURI KRISHNA KITTU 10% Owner
X
Weller Harry R 10% Owner
X
Jones Elaine V Director
X
Barbosa Miguel Chief Scientific Officer
X
Kim Sinil Chief Medical Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-06-20 4 Miller Paul Francis S X D 9.75 -1,000 72,135 703,316
2018-06-20 4 Miller Paul Francis S X D 9.80 -1,054 72,135 706,923
2018-06-19 4 Miller Paul Francis S X D 9.75 -946 74,189 723,343
2018-01-26 4 ORBIMED ADVISORS LLC See Footnotes A I 9.75 715,000 2,029,996
2018-01-26 4 Khuong Chau Quang See Footnotes A I 9.75 715,000 2,029,996
2018-01-26 4 POWELL MICHAEL A I 9.75 150,000 574,972
2018-01-26 4 New Enterprise Associates 14, L.P. A D 9.75 410,000 4,228,940
2018-01-26 4 BARRETT M JAMES See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 BARRIS PETER J See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 BASKETT FOREST See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 Florence Anthony A. Jr. See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 KERINS PATRICK J See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 MOTT DAVID M See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 SANDELL SCOTT D See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 Sonsini Peter W. See Note 1 A I 9.75 410,000 4,228,940
2018-01-26 4 Viswanathan Ravi See Note 1 A I 9.75 410,000 4,228,940
2017-08-28 4 Sonsini Peter W. See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 Viswanathan Ravi See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 BARRETT M JAMES See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 BARRIS PETER J See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 BASKETT FOREST See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 Florence Anthony A. Jr. See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 KERINS PATRICK J See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 MOTT DAVID M See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 SANDELL SCOTT D See Note 2 A I 3,394,439 3,818,940
2017-08-28 4 New Enterprise Associates 14, L.P. A D 3,394,439 3,818,940
2016-12-01 4 Irvin Jon S D 1.4343 280 7,625 10,937
2016-11-11 4 Irvin Jon S D 1.45 -150 7,905 11,462
2016-11-01 4 Irvin Jon S D 1.2839 -280 8,055 10,342
2016-10-11 4 Irvin Jon S D 1.825 -150 8,335 15,211
2016-10-03 4 Irvin Jon S D 1.9254 -250 8,485 16,337
2015-10-06 4 PFIZER INC J D 7.0000 235,855 2,489,364
2015-10-06 4 PFIZER INC P D 7.0000 714,285 2,253,509 15,774,563
2015-10-05 4 PFIZER INC C D 1,539,224 1,539,224
2015-10-06 4 Weller Harry R See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 Weller Harry R See Note 2 J I 31,650 2,114,375
2015-10-06 4 Weller Harry R See Note 2 J I 257,516 1,499,166
2015-10-05 4 Weller Harry R See Note 2 C I 583,559 2,082,725
2015-10-05 4 Weller Harry R See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 Viswanathan Ravi See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 Viswanathan Ravi See Note 2 J I 31,650 2,114,375
2015-10-06 4 Viswanathan Ravi See Note 2 J I 257,516 1,499,166
2015-10-05 4 Viswanathan Ravi See Note 2 C I 583,559 2,082,725
2015-10-05 4 Viswanathan Ravi See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 KOLLURI KRISHNA KITTU See Note 2 P I 7.00 857,142 2,971,517 20,800,619
2015-10-06 4 KOLLURI KRISHNA KITTU See Note 2 J I 31,650 2,114,375
2015-10-06 4 KOLLURI KRISHNA KITTU See Note 2 J I 257,516 1,499,166
2015-10-05 4 KOLLURI KRISHNA KITTU See Note 2 C I 583,559 2,082,725
2015-10-05 4 KOLLURI KRISHNA KITTU See Note 2 C I 1,241,650 1,241,650
2015-10-06 4 New Enterprise Associates 14, L.P. P D 7.00 857,142 2,971,517 20,800,619
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HIMX: Himax Technologies Analysis and Research Report

19h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

Related News Stories

Why Synlogic (SYBX) Could Be a Potential Winner

2018-06-05 zacks
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach. (13-2)

The Eleven: Viking Skyrockets, Global Blood Is Fueling

2018-06-04 seekingalpha
The Eleven is a biotechnology portfolio of eleven stocks we believe have significant upside within a six month to one-year timeframe based upon company fundamentals and upcoming catalysts with good risk/reward ratios. They are listed in a way to reflect top picks and risk tolerance. The first five picks are the top picks (in no particular order). Risks are increased the further away a stock sits from the middle (Picks #6, in the middle of the list, is the least risky). (96-7)

3 Young Biotechs Positioned To Upend Medicine

2018-05-17 seekingalpha
NovoCure is developing a fourth modality of cancer treatment that could be, and is beginning to be, used in supplementation with chemotherapy, radiation, and surgery. (3-6)

Lucky Seven: Omeros Moves, Array Biopharma May Be Next

2018-05-08 seekingalpha
Global Blood Therapeutics posts 1Q earnings and provides update. Given the likelihood of a significant catalyst within a few weeks, we are moving its position to reflect greater risk. (338-4)

Lucky Seven: An Introduction To My Top Biotechnology Picks

2018-05-03 seekingalpha
These seven companies are primarily picked for their current valuation, pipeline prospects, financial figures, and likelihood of near-term share price appreciation. (463-2)